1. Home
  2. ICD-10-PCS Index
  3. New Technology
  4. Anatomical Regions
  5. Introduction
  6. XW0
  • Version 2025
  • Non-Billable Code

2025 ICD-10-PCS Procedure Code XW0

New Technology, Anatomical Regions, Introduction

ICD-10-PCS Code:
XW0
ICD-10-PCS Code for:
New Technology, Anatomical Regions, Introduction
Is Billable?
Not Valid for Submission
Code Navigator:

XW0 is a "header" nonspecific and non-billable procedure code used to indicate the performance of new technology, anatomical regions, introduction.

Table of Contents

  1. Code Information
  2. PCS Table
  3. Other Similar Codes

XW0 PCS Table

In an PCS table each code is represented by up seven alphanumeric characters, with each character in the table respresenting different aspects of the procedure. In the table provided below, each row represents an individual character and includes information about the character's position, designation, label, and procedure notes. For this PCS table the procedure code is in the new technology section and is part of the anatomical regions body system, classified under introduction operation.

Position Designation Character Label Procedures Notes
1 Section X New Technology
2 Body System W Anatomical Regions
3 Operation 0 Introduction

Involves:
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

Other ICD-10-PCS Codes Used for Introduction


  • XW00X27 Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7

  • XW01318 Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8

  • XW01329 Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

  • XW01348 Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8

  • XW0136A Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10

  • XW01397 Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7

  • XW013F5 Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5

  • XW013G6 Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

  • XW013H6 Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

  • XW013K6 Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

  • XW013L9 Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

  • XW013S6 Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

  • XW013S9 Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

  • XW013T6 Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

  • XW013U6 Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

  • XW013V7 Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7

  • XW013W5 Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5

  • XW013W7 Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7

  • XW01X27 Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7

  • XW020D8 Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8

  • XW023S6 Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6

  • XW023T6 Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6

  • XW023U6 Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6

  • XW023V7 Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7

  • XW023W7 Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7

  • XW023X7 Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7

  • XW023Y7 Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7

  • XW03306 Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW03308 Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8

  • XW03326 Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW03336 Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW0333A Introduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW0334A Introduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW03357 Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW03358 Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8

  • XW0335A Introduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW03366 Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW03367 Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW03368 Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8

  • XW03372 Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2

  • XW03377 Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW03378 Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8

  • XW03387 Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW03388 Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8

  • XW0338A Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW03396 Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW03398 Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8

  • XW0339A Introduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW033A6 Introduction of Cefiderocol Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW033A7 Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033B3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3

  • XW033B6 Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW033B7 Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033BA Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW033C6 Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW033C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033CA Introduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW033D6 Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW033DA Introduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW033E5 Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW033E6 Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW033F3 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3

  • XW033F5 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW033F6 Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW033FA Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10

  • XW033G5 Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW033G6 Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW033G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033H5 Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW033H6 Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW033H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033J7 Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033K9 Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9

  • XW033L6 Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6

  • XW033L7 Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

  • XW033P9 Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9

  • XW033Q5 Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW033Q9 Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9

  • XW033R9 Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9

  • XW033S5 Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW033W5 Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

  • XW04306 Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW04308 Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8

  • XW04326 Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW04336 Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW0433A Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW0434A Introduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW04357 Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW04358 Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8

  • XW0435A Introduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW04366 Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW04367 Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW04368 Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

  • XW04372 Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2

  • XW04377 Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW04378 Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

  • XW04387 Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW04388 Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8

  • XW0438A Introduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW04396 Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW04398 Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8

  • XW0439A Introduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW043A6 Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW043A7 Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043B3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3

  • XW043B6 Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW043B7 Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043BA Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW043C6 Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW043C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043CA Introduction of Zanidatamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW043D6 Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW043E5 Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW043E6 Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW043F3 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3

  • XW043F5 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW043F6 Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW043FA Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10

  • XW043G5 Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW043G6 Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW043G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043H5 Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW043H6 Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW043H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043J7 Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043K9 Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9

  • XW043L6 Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6

  • XW043L7 Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

  • XW043P9 Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9

  • XW043Q5 Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW043Q9 Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9

  • XW043R9 Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9

  • XW043S5 Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW043W5 Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5

  • XW053T9 Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9

  • XW0DX38 Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8

  • XW0DX66 Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6

  • XW0DX82 Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2

  • XW0DXF5 Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5

  • XW0DXJ9 Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9

  • XW0DXK8 Introduction of Sabizabulin into Mouth and Pharynx, External Approach, New Technology Group 8

  • XW0DXM6 Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6

  • XW0DXN9 Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9

  • XW0DXR7 Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7

  • XW0G738 Introduction of Maribavir Anti-infective into Upper GI, Via Natural or Artificial Opening, New Technology Group 8

  • XW0G7K8 Introduction of Sabizabulin into Upper GI, Via Natural or Artificial Opening, New Technology Group 8

  • XW0G7M6 Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6

  • XW0G7R7 Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7

  • XW0G886 Introduction of Mineral-based Topical Hemostatic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6

  • XW0H738 Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8

  • XW0H7K8 Introduction of Sabizabulin into Lower GI, Via Natural or Artificial Opening, New Technology Group 8

  • XW0H7M6 Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6

  • XW0H7R7 Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7

  • XW0H7X8 Introduction of Broad Consortium Microbiota-based Live Biotherapeutic Suspension into Lower GI, Via Natural or Artificial Opening, New Technology Group 8

  • XW0H886 Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6

  • XW0J3HA Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10

  • XW0J3JA Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10

  • XW0J3KA Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10

  • XW0J3LA Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10

  • XW0K3HA Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10

  • XW0K3JA Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10

  • XW0K3KA Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10

  • XW0K3LA Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10

  • XW0L3HA Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10

  • XW0L3JA Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10

  • XW0L3KA Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10

  • XW0L3LA Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10

  • XW0M3HA Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10

  • XW0M3JA Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10

  • XW0M3KA Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10

  • XW0M3LA Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10

  • XW0Q316 Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6

  • XW0U0GA Introduction of Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System into Joints, Open Approach, New Technology Group 10

  • XW0V0P7 Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7

  • XW0V3WA Introduction of AGN1 Bone Void Filler into Bones, Percutaneous Approach, New Technology Group 10

What is ICD-10-PCS?

The ICD-10 Procedure Coding System (ICD-10-PCS) is a catalog of procedural codes used by medical professionals for hospital inpatient healthcare settings. The Centers for Medicare and Medicaid Services (CMS) maintain the catalog in the U.S. releasing yearly updates. The 2025 ICD-10-PCS codes are to be used for discharges occurring from October 1, 2024 through September 30, 2025.

Each ICD-10-PCS code has a structure of seven alphanumeric characters and contains no decimals. The first character defines the major "section". Depending on the "section" the second through seventh characters mean different things.